Lebrikizumab monotherapy showed significant improvements in clinical signs, symptoms, and quality of life in patients with moderate-to-severe atopic dermatitis over 16 weeks, according to new research.
The analysis of two phase 3 placebo-controlled studies (ADvocate1 and ADvocate2) looked at lebrikizumab, a selective interleukin-13 inhibitor, administered subcutaneously every two weeks in a randomized group of adults and adolescents with moderate-to-severe AD. Over the 16-week induction period, the authors reported significant improvements in multiple disease dimensions, with statistically significant (P < 0.05) improvements at each 2-week timepoint for the Eczema Area and Severity Index (EASI), Pruritus Numeric Rating Scale (NRS), Sleep-Loss Scale, and Patient-Oriented Eczema Measure (POEM). There were also Improvements in the Dermatology Life Quality Index (DLQI) at 4-week intervals.
Additionally, patients treated with lebrikizumab saw better outcomes compared to placebo at 16 weeks, with an EASI reduction of 71.9% and 75.0% in the two studies (compared to 35.6% and 43.3% in the placebo group). Pruritus NRS decreased by 53.3% and 46.3%, significantly outperforming the placebo (21.4% and 18.0% reduction, respectively). Similar trends were reported for sleep loss, POEM, and DLQI scores.
"Lebrikizumab monotherapy resulted in significant and fast improvements in multiple dimensions of disease (clinical signs, symptoms, and quality of life) over 16 weeks in patients with moderate-to-severe atopic dermatitis," the authors concluded.
Source: Simpson E, et al. Advances in Therapy. 2024. Doi:10.1007/s12325-024-02974-y